Xenon Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$409.2MTTM through 30 Jun 2026
Free Cash Flow -$338.5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-32.9%ROE
-31.6%ROA
Balance Sheet Health
Current Ratio21.02x
Cash & Equivalents$119.5M
Quality Metrics
Altman Z-Score40.69
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $7.5M
Diluted EPS-$4.74TTMFY2025: $-4.36
Dividend
No dividend
Capital Allocation
R&D Spend$352.5M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Neuroscience Pipeline | $0 | View detailsXenon is focused on submitting a New Drug Application (NDA) to the FDA for azetukalner in focal onset seizures (FOS) in the third quarter of 2026, supported by positive Phase 3 X-TOLE2 results. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.